FDA Approves Daratumumab + Carfilzomib and Dexamethasone for R/R MM

On August 20, 2020 the U.S. Food and Drug Administration (FDA) approved Darzalex® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received one to three previous lines of therapy.

Read Janssen's announcement.

Read the FDA announcement.

Posted 8/21/2020